Vall d´Hebron Institute of Oncology (VHIO) is a cancer research center associated with Vall d’Hebron University Hospital that combines translational and clinical research to address the most pressing unmet needs in cancer research and patient care. For more information, including a description of the research programs, please visit: www.vhio.net

VHIO invites applications from outstanding young investigators interested in launching an independent research laboratory, with a particular emphasis on cell-based immunotherapy in hematological malignancies.

Research themes for this position include:

  • Development of immune-based personalized therapeutics including CAR-T cells and other cellular therapies.
  • Translational immunology using collected samples from more than 200 CAR T-cell patients.
  • Drug-testing and development in partnership with several international companies.

What do we offer:

We offer the expertise of a leading team in the field of CAR T-cells and cellular therapy in Europe with ongoing research projects in partnership with leading institutions in Germany, France and United Kingdom.

The successful candidate will be provided with laboratory space, a competitive start-up package, and access to state-of-the-art core units and facilities (e.g.: genomics, proteomics, molecular pathology etc) to develop their research proposal. They will be expected to work within a highly collaborative and interdisciplinary environment in close interaction with researchers in the CAR-T Program and the Experimental Haematology group at VHIO.

 Application:

Applicants should include a full CV (including bibliography and current/past competitive funding), a letter of intent, a brief (3-page max) research proposal, and the names of at least three references. Expressions of interest will be reviewed by the VHIO’s Internal Scientific Committee. Materials should be combined in a single PDF and sent by email to selecciorrhh@vhio.net

Applications will be immediately reviewed by the internal scientific committee and will be considered until June 1st, 2023.

 

Spread the love